Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Investor Presentation (April 2006)
12 slides from Vita Life Sciences's investor presentation, Apr 12, 2006
Slide 1: Meeting of Noteholders and Shareholders
MEETING OF NOTEHOLDERS AND SHAREHOLDERS 12 April 2006 AGENDA 1. Welcome 2. Reports: • Chairman's introduction • Executive Report 3. Business: • Receiving the Resolutions in relation to the meeting 4. Question Time 5. Close 1
Slide 2: Underlying Operating Performance 2005
VITA LIFE Underlying Operating Performance 2005 (AUD $ Million) 2005** 2004 2003 2002 Sales from operating activities 21.6 22.8 23.2 14.1 Operating expenses (18.5) (19.8) (21.0) (29.0) Profit from operations 3.1 3.0 2.2 (14.9) Legal (1.0) (1.3) (1.3) (2.8) Provisions & write offs (1.3) (1.0) (8.5) (
Slide 3: Profit & Loss 2005 / Vita Medical and Cyclopharm
VITA LIFE SCIENCES Profit & Loss 2005 (AUD$ Million) Vita Medical VitaHealth Corporate VLS Gross Sales 8.8 12.8 0.0 21.6 Unaudited 2.7 (1.1) (4.4)* (2.8) PBT *includes write off relating to Supplements World 4 VITA MEDICAL and CYCLOPHARM
Slide 4: Cyclopharm Underlying Performance 2005
CYCLOPHARM Underlying Performance 2005 (AUD$ Million) 2003 2004 2005 Sales 7.7 8.7 8.8 PBIT 1.8 2.8 2.7 PAS Unit Sales Generator Sales & Placements 3300 90 3200 80 70 3100 60 3000 50 2900 40 2800 30 20 2700 10 2600 0 2003 2004 2005 2003 2004 2005 6 CYCLOPHARM Underlying Performance 2005 • Revenue is
Slide 5: Outlook
CYCLOPHARM Outlook • New Technegas Plus launched in fourth quarter 2005 • Strong pre orders for Technegas Plus (55 pre orders already) • New software being developed by leading software house to increase market acceptance of Technegas • Growth to continue in China, Canada and Latin America • New dis
Slide 6: New Drug Application
CYCLOPHARM New Drug Application • Commenced the trials in December 2005. • 3 Canadian hospitals signed up – Toronto General, Memorial University, CDHA Halifax • 3 Australian hospitals signed up – Royal Perth, Royal North and St George • Program expected for completion in 2006. – Depends on patient c
Slide 7: Future Plans
CYCLOPHARM Future Plans Cyclotrons, PET and FDG supply: Asia/Pacific Entered heads of agreement to be exclusive licensee for Cyclopharma Laboratories SA technology. Business initiatives expected to be developed during second half of 2006 onwards 12 CYCLOPHARM Pro forma balance sheet 13
Slide 8: Pro forma group structure
CYCLOPHARM Pro forma group structure 14 15
Slide 9: Vita Health Underlying Operating Performance 2005
Vita Health Underlying Operating Performance 2005 (AUD $ 000) 2005 2004 2003 Sales Malaysia 3.9 5.7 6.0 Singapore 3.2 4.4 5.1 Australia 5.7 4.9 4.4 12.8 15.0 15.5 Direct selling costs (9.2) (10.6) (9.5) Operating expenses (4.7) (6.6) (11.9) Profit before tax (1.1) (2.0) (5.9) 16 Vita Health Underlyi
Slide 10: Initiative to improve business in 2006
Vita Health Initiative to improve business in 2006 • Improve supply chain and inventory lifecycle • Intensify product training with the aim of promoting selected items aggressively • Aggressively recruit product development team • New sets of Standard Group Operating Policies and Procedures – implem
Slide 11: Legal update
VITA LIFE SCIENCES Legal update • The company continues to defend its position re Nordion, – malicious and false emails have caused lengthy delays • The company continue to defend and cross claim against Ms Kate Fraser over the purchase of Herbs of Gold • The company settled with Mr Koziol 20 VITA L
Slide 12: Thank You
YY) VITA LIFE SCIENCES Thank You
Vita Life Sciences — Investor Presentation (April 2006) on 6ix